E

Entheon Biomedical Corp
OTC:ENTBF

Watchlist Manager
Entheon Biomedical Corp
OTC:ENTBF
Watchlist
Price: 0.079 USD Market Closed
Market Cap: $699.9k

Entheon Biomedical Corp
Investor Relations

Entheon Biomedical Corp. is a biotechnology company, which engages in developing and commercializing dimethyltryptamine based psychedelic therapeutic products. The company is headquartered in Coquitlam, British Columbia. The company went IPO on 2018-05-03. The firm focuses on developing a portfolio of Dimethyltryptamine (DMT) based psychedelic therapeutic products for treating addiction and substance use disorders. The Company’s DMT is advancing and sustaining new models of psychedelic-assisted therapy. The firm is developing a combination of genetic and predictive data analysis to ensure the safest psychedelic treatment possible. The firm is also developing a predictive biomarker response platform in partnership with Divergence NeuroTech. Its biomarker platform is artificial intelligence and machine learning and prescribes suitable psychedelic treatments and provides real-time feedback during a psychedelic event, and informs the development of a post-therapy system of patient-specific support.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Mr. Timothy Ko
President, CEO & Director
No Bio Available
Mr. Soo-Whan Kim
Interim Chief Financial Officer
No Bio Available
Dr. Brian E. Jahns Pharm.D.
Chief Business Officer
No Bio Available
Ms. Kelly Pladson
Corporate Secretary
No Bio Available

Contacts

Address
BRITISH COLUMBIA
Coquitlam
211-3030 Lincoln Avenue
Contacts
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett